Novavax reached a settlement with Gavi, the Vaccine Alliance, after t | International vaccine partnership Gavi has ...

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

The company is on the lookout for partners to advance vaccine contenders. Novavax Inc. is starting to look like a vaccine development company again. The Gaithersburg biotech is two years into its ...

Novavax in May had signed a deal worth at least ... for the COVID-flu combination and up to $200 million for each new vaccine launch using its Matrix-M formulation. "We will be generating revenue ...

The Novavax's COVID vaccine was approved by the US Food and Drug Administration for people age 12 and older in August 2024. This places it alongside Moderna's and Pfizer-BioNTech's refreshed formulas.

Novavax's late-stage pipeline features a stand-alone flu vaccine and a combination COVID/flu one. These investigational ...

The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate. Also Read: Wegovy Maker Novo Nordisk To Buy Novavax ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

Novavax aims to achieve profitability by 2027 through cost reductions and potential milestone payments from Sanofi's CIC vaccine launch, but the overall picture does not inspire too much confidence.

The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have ...

Investing.com -- Shares of vaccine manufacturers Moderna Inc (BMV:MRNA) (NASDAQ:MRNA), Novavax Inc (NASDAQ:NVAX), and Pfizer Inc (NYSE:PFE) fell in today’s trading session, down 5%, 3% ...